September 18, 2014 3:17 AM ET


Company Overview of Diartis Pharmaceuticals, Inc.

Company Overview

Diartis Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutic proteins for the treatment of metabolic disorders. Its development portfolio includes VRS-859, a glucagon-like peptide-1 analog that provides improved therapeutic outcomes for Type 2 diabetic patients. The company was incorporated in 2010 and is based in Redwood City, California.

275 Shoreline Drive

Suite 450

Redwood City, CA 94065

United States

Founded in 2010



Key Executives for Diartis Pharmaceuticals, Inc.

Age: 49
Senior Vice President of Business Development
Age: 45
Clinical Advisor
Clinical Advisor
Clinical Advisor
Compensation as of Fiscal Year 2014.

Diartis Pharmaceuticals, Inc. Key Developments

Diartis Pharmaceuticals, Inc. Presents VRS-859 Positive Clinical Results for Type 2 Diabetes

Diartis Pharmaceuticals, Inc. is presenting positive data from its completed Phase 1 multicenter clinical trial of VRS-859 (exenatide-XTEN) at the European Association for the Study of Diabetes (EASD) 48th Annual Meeting which began on October 1 in Berlin-Charlottenburg. VRS-859, a long-acting glucagon-like peptide-1 (GLP-1) analog, is being developed as a once monthly treatment for patients with type 2 diabetes mellitus (T2DM). The Phase 1 multicenter, blinded, placebo-controlled, single-ascending dose study was designed to evaluate the safety and tolerability of VRS-859 as well as the ability to maintain glycemic control for one month in T2DM patients after a single dose. The Phase 1 results in T2DM patients demonstrate that all doses administered (up to 200 mg) were well tolerated and no unexpected adverse events were noted. Furthermore, the PK of VRS-859 in these patients was dose linear and comparable to the profile predicted from preclinical studies, validating the half-life extension capability of the XTEN technology and supporting a once monthly dosing regimen for VRS-859. These results support the company's plan to conduct a 6-month repeat dose study to determine a safe and efficacious subcutaneous dose of VRS-859 in patients with T2DM. About VRS-859 The compound has been designed to provide improved therapeutic outcomes for T2DM patients including robust and sustained improvements in HbA1c, improved tolerability, prolonged half-life (up to monthly dosing), as well as enhanced administration of a liquid formulation via a fine-gauge needle. It is hoped that upon successful development, VRS-859 may allow T2DM patients to safely manage their glucose with a therapy that is superior to current treatments for diabetes.

Similar Private Companies By Industry

Company Name Region
Vasculox, Inc. United States
Proliant Inc. United States
GenBase, Inc. United States
Tutela Medicus, Inc. United States
QIAGEN Gaithersburg, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Diartis Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at